Literature DB >> 29275471

Oncolytic Virotherapy and the Tumor Microenvironment.

Sara E Berkey1, Steve H Thorne2,3, David L Bartlett2.   

Abstract

Oncolytic viral therapy is a promising approach to treat many malignancies, including breast, colorectal, hepatocellular, and melanoma. The best results are seen when using "targeted and armed" viruses. These are viruses that have been genetically modified to selectively replicate within cancer cells and express specific transgenes that alter the tumor microenvironment to inhibit tumor progression. The products of these transgenes induce cell death, make the virus less virulent, compromise tumor vascularity, and are capable of modulating or enhancing the immune system-such as cytokines and chemokines. In addition, oncolytic viruses can induce anti-vascular effects and disrupt the extracellular matrix to improve viral spread within the tumor. Oncolytic viruses also improve crosstalk between fibroblasts, cytokine-induced killer cells, and cancer cells within the microenvironment, leading to enhanced tumor cell death.

Entities:  

Keywords:  Cytokine expression; Extracellular matrix; Immune activation; Oncolytic virus; Vascular inhibition

Mesh:

Year:  2017        PMID: 29275471     DOI: 10.1007/978-3-319-67577-0_11

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  11 in total

1.  Comprehensive characterization of tumor immune landscape following oncolytic virotherapy by single-cell RNA sequencing.

Authors:  Divya Ravirala; Guangsheng Pei; Zhongming Zhao; Xiaoliu Zhang
Journal:  Cancer Immunol Immunother       Date:  2021-10-30       Impact factor: 6.968

2.  Oncolytic adenovirus promotes vascular normalization and nonclassical tertiary lymphoid structure formation through STING-mediated DC activation.

Authors:  Teng He; Zhixing Hao; Mingjie Lin; Zhongwei Xin; Yongyuan Chen; Wei Ouyang; Qi Yang; Xiaoke Chen; Hui Zhou; Wanying Zhang; Pin Wu; Feng Xu
Journal:  Oncoimmunology       Date:  2022-07-01       Impact factor: 7.723

Review 3.  Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy.

Authors:  Yalei Zhang; Ye Li; Kun Chen; Ling Qian; Peng Wang
Journal:  Cancer Cell Int       Date:  2021-05-13       Impact factor: 5.722

Review 4.  Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials.

Authors:  Christopher J LaRocca; Susanne G Warner
Journal:  Clin Transl Med       Date:  2018-11-14

Review 5.  Mesenchymal Stem Cell Expressing TRAIL as Targeted Therapy against Sensitised Tumour.

Authors:  Kamal Shaik Fakiruddin; Nadiah Ghazalli; Moon Nian Lim; Zubaidah Zakaria; Syahril Abdullah
Journal:  Int J Mol Sci       Date:  2018-07-27       Impact factor: 5.923

6.  Overexpression of Smac by an Armed Vesicular Stomatitis Virus Overcomes Tumor Resistance.

Authors:  Weike Li; Ravi Chakra Turaga; Xin Li; Malvika Sharma; Zahra Enadi; Sydney Nicole Dunham Tompkins; Kyle Christian Hardy; Falguni Mishra; Jun Tsao; Zhi-Ren Liu; Daping Fan; Ming Luo
Journal:  Mol Ther Oncolytics       Date:  2019-06-04       Impact factor: 7.200

7.  Combining IL-10 and Oncolytic Adenovirus Demonstrates Enhanced Antitumor Efficacy Through CD8+ T Cells.

Authors:  Duo Chen; Luyu Huang; Haiyu Zhou; Yuhui Zhang
Journal:  Front Immunol       Date:  2021-02-26       Impact factor: 7.561

Review 8.  Oncolytic Virotherapy in Solid Tumors: The Challenges and Achievements.

Authors:  Ke-Tao Jin; Wen-Lin Du; Yu-Yao Liu; Huan-Rong Lan; Jing-Xing Si; Xiao-Zhou Mou
Journal:  Cancers (Basel)       Date:  2021-02-03       Impact factor: 6.639

Review 9.  Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction.

Authors:  Amirhossein Mardi; Anastasia V Shirokova; Rebar N Mohammed; Ali Keshavarz; Angelina O Zekiy; Lakshmi Thangavelu; Talar Ahmad Merza Mohamad; Faroogh Marofi; Navid Shomali; Amir Zamani; Morteza Akbari
Journal:  Cancer Cell Int       Date:  2022-04-29       Impact factor: 6.429

10.  Pharmacological Inhibition of WEE1 Potentiates the Antitumoral Effect of the dl922-947 Oncolytic Virus in Malignant Mesothelioma Cell Lines.

Authors:  Carmelina Antonella Iannuzzi; Paola Indovina; Iris Maria Forte; Sarah Di Somma; Anna Maria Malfitano; Martina Bruno; Giuseppe Portella; Francesca Pentimalli; Antonio Giordano
Journal:  Int J Mol Sci       Date:  2020-10-04       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.